兔抗AKT1 (Phospho-Thr308)多克隆抗體

Background:

The serine-threonine protein kinase encoded by the AKT1 gene is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3-kinase. In the developing nervous system AKT is a critical mediator of growth factor-induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery. Mutations in this gene have been associated with the Proteus syndrome. Multiple alternatively spliced transcript variants have been found for this gene.

Applications:

WB, IHC, IF

Name of antibody:

AKT1(Phospho-Thr308)

Immunogen:

Peptide sequence around phosphorylation site of threonine 308 (M-K-T(p)-F-C) derived from Human AKT1

Full name:

AKT serine/threonine kinase 1

Synonyms:

AKT; PKB; RAC; CWS6; PRKBA; PKB-ALPHA; RAC-ALPHA

SwissProt:

P31749

IHC positive control:

Human lung carcinoma tissue

IHC Recommend dilution:

50-100

WB Predicted band size:

56 kDa

WB Positive control:

Hela cells treated with EGF, serum or both

WB Recommended dilution:

500-1000

IF Positive control:

Hela cells

IF Recommended dilution

100-200